Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Urology and
1 other channel

Journal Scan / Research · August 26, 2019

Cost Effectiveness of Abiraterone vs Docetaxel in the Treatment of Hormone-Naïve Prostate Cancer

Urologic Oncology: Seminars and Original Investigations

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Joshua Cohn MD, FPMRS

Urologic Oncology: Seminars and Original Investigations
Cost Effectiveness of Abiraterone Versus Docetaxel in the Treatment of Metastatic Hormone-Naïve Prostate Cancer
Urol. Oncol 2019 Aug 06;[EPub Ahead of Print], C Ramamurthy, EA Handorf, AF Correa, JR Beck, DM Geynisman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated